ClinicalTrials.gg
RecruitingNCT06451315IAVASCUpdated Jun 13, 2024

REGISTRY on the Implementation of Artificial Intelligence in the Automatic Analysis of Vascular Network Segmentation

An observational study in Abdominal Aortic Aneurysm, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-13.

Sponsored by University Hospital, Bordeaux · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Aortic Aneurysm, Abdominal with a site in France — 10 open to participants now, 13 under way, none of them phase 3. Aortic Aneurysm, Abdominal · France.

Planned enrollment
14th of 33
250 · median 181
Started
2024
with 1 other
Observational
33 of 59
4 open now
Primary completion
2024-07
later than 1 of 12 live
Registered
56th of 59
by date
Lead sponsor
3 of 59
University Hospital, Bordeaux

Among the 59 studies in Aortic Aneurysm, Abdominal with a site in France, this one is the 14th largest by planned enrollment of the 33 observational ones that give a count, is one of 2 that started in 2024, is one of 33 observational ones, reaches primary completion later than 1 of the 12 other live ones, and was the 56th registered.

Aortic Aneurysm, Abdominal

467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.

Browse Aortic Aneurysm, Abdominal studies →

Open to participants now

10 of the 59 studies in Aortic Aneurysm, Abdominal with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 66 Aortic Aneurysm, Abdominal studies recruiting now, 52 (79%) set no upper age limit and 3 (5%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Aortic Aneurysm, Abdominal with a site in France, or all of them as a file.
02

Study summary

The team hypothesizes that fully automatic analysis of AAA could provide increased performance (decreased duration of segmentation with increased reproducibility and decreased inter and intraobserver variability) to detect aortic aneurysmal sac enlargement (volumes and diameters) and predict the risk of complications during the procedure and during follow-up (MAE, MACE, MALE, Stroke) compared to standard methods of measurement relying on approximate maximum sac diameter.

Read the detailed description

An abdominal aortic aneurysm (AAA) is an abnormal dilation of the abdominal aortic wall. The most catastrophic consequence of AAA increase evolution is aortic rupture, which still results in high morbidity and mortality. Accurate measurement of AAAs is necessary to predict the risk of rupture during evolution, to take adequate decisions to treat or not the patient as well as detect general and technical risk factors and to follow aneurysm sac behavior after endovascular aortic repair (EVAR).

Despite the widespread use of diameter measurements in clinical trials and its ease of ascertainment in clinical practice for monitoring of AAAs; clinical decision-making regarding the timing of aneurysm repair and even surveillance of sac expansion after EVAR, several studies have concluded that the diameter may not be reliable as a rupture risk criterion and that it should be replaced by more specifics criteria.

Volumetric assessment of the aneurysm is bound to be a better predictor of AAA expansion and risk of rupture. Recently, there has been considerable progress in segmentation software, allowing a semi-automatic calculation of accurate volumes from CTAs. However, despite ample evidence, volumetry has largely remained in the research domain and is still not carried out in most institutions. The major reason is that segmentation methods are time-consuming, they do not allow co-registration of interval studies and they require dedicated software and skilled technicians, which may be difficult to organize.

Innovative software PREAVAorta of Nurea company, using artificial intelligence with deep learning approaches, is able to reconstruct automatically the vascular structures from CT scans. As current solutions only reconstruct the lumen, Nurea's software also segments automatically aneurysms and associated thrombus. With this reconstruction, the software is able to provide diameters (and in particular maximum diameters) but also aneurysmal sac volume. It is the first solution providing automatic AAA volume and comparative evolution during follow-up. In addition, the software provides distances between anatomic points, calcification volume and measurement evolutions between different time points. The software also automatically detects and quantifies calcifications and stenosis on peripheral arteries, which is currently evaluated on the same or independent CT scans for predictive factor analysis, especially with regard to stroke risk for carotid stenosis and accesses, technical difficulties and predictors or MACE (Major Adverse Coronary Event) or MALE (Major Adverse Limb Event) for iliac and femoral arteries.

03

Conditions studied

  • Abdominal Aortic Aneurysm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The patient came to the vascular surgery unit for his post-operative follow-up visit who have had surgery for Abdominal Aortic Aneurysm

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥18 years of age
  • AAA treated with EVAR between

    • ≥50mm
    • or ≥5mm increase in 6 months
  • The subject is legally competent, has been informed of the nature, the scope, and the relevance of the study and has not manifested an opposition to participate.
  • Available for set-up and proper implementation of follow-up visits (standard of care) throughout the duration of the registry

Exclusion criteria

Exclusion Criteria:

  • Advancing Alzheimer's disease or socially dependent patient
  • Opposition to the use of their data for this research
  • supposed to be inferior to 2 years
  • Pregnant woman
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • Abdominal Aortic Aneurysm (AAA) treated with EndoVascular Aneurysm Repair (EVAR)

    Male or female ≥18 years of age with AAA treated with EVAR between ≥50mm or ≥5mm increase in 6 months. The subject is legally competent, has been informed of the nature, the scope, and the relevance of the study and has not manifested an opposition to participate. He is available for set-up and proper implementation of follow-up visits (standard of care) throughout the duration of the registry

    Procedure: Analyze CTscans pre-operatively by Nurea System · Procedure: Analyze CTscans pre-operatively by hospital practitioner

Interventions

  • ProcedureAnalyze CTscans pre-operatively by Nurea System

    CTscans will be analyzed pre-operatively (6 months before intervention) and post-operatively with an early control scan (up to one-month post-EVAR), compared to a 3, 6 and 12-month control scan by system develop by Nurea

  • ProcedureAnalyze CTscans pre-operatively by hospital practitioner

    CTscans will be analyzed pre-operatively (6 months before intervention) and post-operatively with an early control scan (up to one-month post-EVAR), compared to a 3, 6 and 12-month control scan by an hospital practitioner

06

What researchers measure

Primary outcomes

  1. global volume measure of the aneurysm

    global volume measure of the aneurysm by CT-scan. Data are retrospectively collected from the preoperative period (6 months before intervention), during hospitalisation and at systematic follow-up visits at 3, 6 and 12 months after surgery.

    Time frame: 6 months before surgery

  2. global volume measure of the aneurysm

    global volume measure of the aneurysm by CT-scan. Data are retrospectively collected from the preoperative period (6 months before intervention), during hospitalisation and at systematic follow-up visits at 3, 6 and 12 months after surgery.

    Time frame: Day 3

  3. global volume measure of the aneurysm

    global volume measure of the aneurysm by CT-scan. Data are retrospectively collected from the preoperative period (6 months before intervention), during hospitalisation and at systematic follow-up visits at 3, 6 and 12 months after surgery.

    Time frame: Month 3

  4. global volume measure of the aneurysm

    global volume measure of the aneurysm by CT-scan. Data are retrospectively collected from the preoperative period (6 months before intervention), during hospitalisation and at systematic follow-up visits at 3, 6 and 12 months after surgery.

    Time frame: Month 6

  5. global volume measure of the aneurysm

    global volume measure of the aneurysm by CT-scan. Data are retrospectively collected from the preoperative period (6 months before intervention), during hospitalisation and at systematic follow-up visits at 3, 6 and 12 months after surgery.

    Time frame: Month 12

Secondary outcomes

  1. lumen volume measure of the aneurysm

    lumen volume measure of the aneurysm by CT-scan. Data are retrospectively collected from the preoperative period (6 months before intervention), during hospitalisation and at systematic follow-up visits at 3, 6 and 12 months after surgery.

    Time frame: 6 months before surgery

  2. lumen volume measure of the aneurysm

    lumen volume measure of the aneurysm by CT-scan. Data are retrospectively collected from the preoperative period (6 months before intervention), during hospitalisation and at systematic follow-up visits at 3, 6 and 12 months after surgery.

    Time frame: Day 3

  3. lumen volume measure of the aneurysm

    lumen volume measure of the aneurysm by CT-scan. Data are retrospectively collected from the preoperative period (6 months before intervention), during hospitalisation and at systematic follow-up visits at 3, 6 and 12 months after surgery.

    Time frame: Month 3

  4. lumen volume measure of the aneurysm

    lumen volume measure of the aneurysm by CT-scan. Data are retrospectively collected from the preoperative period (6 months before intervention), during hospitalisation and at systematic follow-up visits at 3, 6 and 12 months after surgery.

    Time frame: Month 6

  5. lumen volume measure of the aneurysm

    lumen volume measure of the aneurysm by CT-scan. Data are retrospectively collected from the preoperative period (6 months before intervention), during hospitalisation and at systematic follow-up visits at 3, 6 and 12 months after surgery.

    Time frame: Month 12

  6. thrombus volume measure of the aneurysm

    thrombus volume measure of the aneurysm by CT-scan. Data are retrospectively collected from the preoperative period (6 months before intervention), during hospitalisation and at systematic follow-up visits at 3, 6 and 12 months after surgery.

    Time frame: 6 months before surgery

  7. thrombus volume measure of the aneurysm

    thrombus volume measure of the aneurysm by CT-scan. Data are retrospectively collected from the preoperative period (6 months before intervention), during hospitalisation and at systematic follow-up visits at 3, 6 and 12 months after surgery.

    Time frame: Day 3

  8. thrombus volume measure of the aneurysm

    thrombus volume measure of the aneurysm by CT-scan. Data are retrospectively collected from the preoperative period (6 months before intervention), during hospitalisation and at systematic follow-up visits at 3, 6 and 12 months after surgery.

    Time frame: Month 3

  9. thrombus volume measure of the aneurysm

    thrombus volume measure of the aneurysm by CT-scan. Data are retrospectively collected from the preoperative period (6 months before intervention), during hospitalisation and at systematic follow-up visits at 3, 6 and 12 months after surgery.

    Time frame: Month 6

  10. thrombus volume measure of the aneurysm

    thrombus volume measure of the aneurysm by CT-scan. Data are retrospectively collected from the preoperative period (6 months before intervention), during hospitalisation and at systematic follow-up visits at 3, 6 and 12 months after surgery.

    Time frame: Month 12

  11. calcification volume measure of the aneurysm

    calcification volume measure of the aneurysm by CT-scan. Data are retrospectively collected from the preoperative period (6 months before intervention), during hospitalisation and at systematic follow-up visits at 3, 6 and 12 months after surgery.

    Time frame: 6 months before surgery

  12. calcification volume measure of the aneurysm

    calcification volume measure of the aneurysm by CT-scan. Data are retrospectively collected from the preoperative period (6 months before intervention), during hospitalisation and at systematic follow-up visits at 3, 6 and 12 months after surgery.

    Time frame: Day 3

  13. calcification volume measure of the aneurysm

    calcification volume measure of the aneurysm by CT-scan. Data are retrospectively collected from the preoperative period (6 months before intervention), during hospitalisation and at systematic follow-up visits at 3, 6 and 12 months after surgery.

    Time frame: Month 3

  14. calcification volume measure of the aneurysm

    calcification volume measure of the aneurysm by CT-scan. Data are retrospectively collected from the preoperative period (6 months before intervention), during hospitalisation and at systematic follow-up visits at 3, 6 and 12 months after surgery.

    Time frame: Month 6

  15. calcification volume measure of the aneurysm

    calcification volume measure of the aneurysm by CT-scan. Data are retrospectively collected from the preoperative period (6 months before intervention), during hospitalisation and at systematic follow-up visits at 3, 6 and 12 months after surgery.

    Time frame: Month 12

07

Study locations

1 of 1 sites recruiting
  • Service de Chirurgie Vasculaire, Hôpital Pellegrin-tripode, CHU de Bordeaux
    Bordeaux cedex, 33076, France
    Recruiting
    • Eric Ducasse, MD, PhD · Contacteric.ducasse@chu-bordeaux.fr · 33 (0) 5 56 79 55 25
    • Eric DUCASSE, MD, PhD · Principal investigator
    • Caroline CARADU, MD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Jul 2024, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2024
First posted
Jun 11, 2024
StartActual
Jan 30, 2024
Primary completionEst.
Jul 15, 2024
CompletionEst.
Jul 15, 2024
Last update
Jun 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06451315
Collaborators
Nurea
Responsible party
Sponsor
First posted
Jun 11, 2024
Start date
Jan 30, 2024
Primary completion
Jul 15, 2024 (estimated)
Completion
Jul 15, 2024 (estimated)
Last update
Jun 13, 2024

Study contacts

Eric DUCASSE, MD, PhD
Contact
eric.ducasse@chu-bordeaux.fr
+33 5 56 79 55 25
Olivier DELORME
Contact
olivier.delorme@chu-bordeaux.fr
+ 33 5 57 65 60 05
Eric DUCASSE, MD, PhD
principal investigator · University Hospital, Bordeaux

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion